PMID- 23204847
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121204
LR  - 20231104
IS  - 1178-6965 (Electronic)
IS  - 1178-6965 (Linking)
VI  - 5
DP  - 2012
TI  - Allergic bronchopulmonary aspergillosis treated successfully for one year with 
      omalizumab.
PG  - 65-70
LID - 10.2147/JAA.S34579 [doi]
AB  - BACKGROUND: Current therapy for allergic bronchopulmonary aspergillosis (ABPA) 
      uses oral corticosteroids, exposing patients to the adverse effects of these 
      agents. There are reports of the steroid-sparing effect of anti-IgE therapy with 
      omalizumab for ABPA in patients with cystic fibrosis (CF), but there is little 
      information on its efficacy against ABPA in patients with bronchial asthma 
      without CF. OBJECTIVE: To examine the effects of omalizumab, measured by asthma 
      control, blood eosinophilia, total serum immunoglobulin E (IgE), oral 
      corticosteroid requirements, and forced expiratory volume spirometry in patients 
      with ABPA and bronchial asthma. METHODS: A retrospective review of charts from 
      2004-2006 of patients treated with omalizumab at an academic allergy and 
      immunology practice in the Bronx, New York were examined for systemic steroid and 
      rescue inhaler usage, serum immunoglobulin E levels, blood eosinophil counts, and 
      asthma symptoms, as measured by the Asthma Control Test (ACT). RESULTS: A total 
      of 21 charts were screened for the diagnosis of ABPA and bronchial asthma. Four 
      patients with ABPA were identified; two of these patients were male. The median 
      monthly systemic corticosteroid use at 6 months and 12 months decreased from 
      baseline usage. Total serum IgE decreased in all patients at 12 months of 
      therapy. Pre-bronchodilator forced expiratory vital capacity at one second 
      (FEV(1)) was variable at 1 year of treatment. There was an improvement in Asthma 
      Control Test (ACT) symptom scores for both daytime and nighttime symptoms. 
      CONCLUSIONS: Treatment with omalizumab creates a steroid-sparing effect, reduces 
      systemic inflammatory markers, and results in improvement in ACT scores in 
      patients with ABPA.
FAU - Collins, Jennifer
AU  - Collins J
AD  - New York Eye and Ear Infirmary, New York, NY.
FAU - Devos, Gabriele
AU  - Devos G
FAU - Hudes, Golda
AU  - Hudes G
FAU - Rosenstreich, David
AU  - Rosenstreich D
LA  - eng
PT  - Case Reports
DEP - 20121108
PL  - New Zealand
TA  - J Asthma Allergy
JT  - Journal of asthma and allergy
JID - 101543450
PMC - PMC3508546
OTO - NOTNLM
OT  - allergic bronchopulmonary aspergillosis
OT  - asthma
OT  - omalizumab
EDAT- 2012/12/04 06:00
MHDA- 2012/12/04 06:01
PMCR- 2012/11/08
CRDT- 2012/12/04 06:00
PHST- 2012/12/04 06:00 [entrez]
PHST- 2012/12/04 06:00 [pubmed]
PHST- 2012/12/04 06:01 [medline]
PHST- 2012/11/08 00:00 [pmc-release]
AID - jaa-5-065 [pii]
AID - 10.2147/JAA.S34579 [doi]
PST - ppublish
SO  - J Asthma Allergy. 2012;5:65-70. doi: 10.2147/JAA.S34579. Epub 2012 Nov 8.